1
|
Caroleo B, Migliore A, Cione E, Zampogna S, Perticone F, Sarro GD, Gallelli L. Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report. Curr Drug Saf 2019; 14:147-150. [PMID: 30648521 DOI: 10.2174/1574886314666190114124625] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 12/31/2018] [Accepted: 01/03/2019] [Indexed: 01/22/2023]
Abstract
BACKGROUND Either direct or indirect tumor necrosis factor (TNF)-alpha blockers are usually used to treat psoriatic arthritis (PA), but their use can increase susceptibility to infectious diseases. CASE PRESENTATION We report a rare case of double skin-knee wound and lung non-tubercular infection in a patient with PA under TNF-alpha blockers therapy. About 1 year after the beginning of adalimumab, a 48-year-old smoker suffering of PA was hospitalized for the skin-knee wound. RESULTS Clinical evaluation and biochemical markers excluded the presence of a systemic disease, and a skin infection sustained by leishmaniasis probably related to adalimumab was diagnosed (Naranjo score: 6). Adalimumab was discontinued and oral treatment with apremilast and topical treatment with meglumine antimoniate was started with a complete remission of skin wound in 2 weeks. About 7 months later when the patient was under apremilast treatment, he presented to our observation for dyspnea, cough and fever. High-Resolution Computer Tomography (HRCT) chest highlighted alveolar involvement with centrilobular small nodules, branching linear and nodular opacities. Microbiological culture of both broncho-alveolar lavage fluid and sputum documented an infection sustained by nontuberculous mycobacteria. Even if apremilast treatment probably-induced lung infection, we can't exclude that it worsened a clinical condition induced by adalimumab. Apremilast was stopped and an empirical antitubercular treatment was started. Patient's breathlessness and cough improved as confirmed also by HRCT chest. CONCLUSION This case highlights the importance to consider the possibility to develop leishmaniasis and/or non-tubercular mycobacterial infection in patients treated with TNF-alpha inhibitors.
Collapse
Affiliation(s)
- Benedetto Caroleo
- Department of Medical and Surgical Science, School of Medicine, University of Catanzaro and Elderly Disease Operative Unit Mater Domini Hospital, Catanzaro, Italy
| | | | - Erika Cione
- Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Cosenza, Italy
| | - Stefania Zampogna
- Operative Unit of Pediatric diseases, Pugliese Ciaccio Hospital, Catanzaro, Italy
| | - Francesco Perticone
- Department of Medical and Surgical Science, School of Medicine, University of Catanzaro and Elderly Disease Operative Unit Mater Domini Hospital, Catanzaro, Italy
| | - Giovambattista De Sarro
- Department of Health Science, University of Catanzaro and Clinical Pharmacology and Pharmacovigilance Operative Unit, Mater Domini Hospital, Catanzaro, Italy
| | - Luca Gallelli
- Department of Health Science, University of Catanzaro and Clinical Pharmacology and Pharmacovigilance Operative Unit, Mater Domini Hospital, Catanzaro, Italy
| |
Collapse
|
2
|
Rahman MM, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissig PL, Berg RL, Page D, Hansen RA. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Epilepsy Res 2017. [PMID: 28641219 DOI: 10.1016/j.eplepsyres.2017.06.007] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
OBJECTIVE Despite the cost saving role of generic anti-epileptic drugs (AEDs), debate exists as to whether generic substitution of branded AEDs may lead to therapeutic failure and increased toxicity. This study compared adverse event (AE) reporting rates for brand vs. authorized generic (AG) vs. generic AEDs. Since AGs are pharmaceutically identical to brand but perceived as generics, the generic vs. AG comparison minimized potential bias against generics. METHODS Events reported to the U.S. Food and Drug Administration Adverse Event Reporting System between January 2004 to March 2015 with lamotrigine, carbamazepine, and oxcarbazepine listed as primary or secondary suspect were classified as brand, generic, or AG based on the manufacturer. Disproportionality analyses using the reporting odds ratio (ROR) assessed the relative rate of reporting of labeled AEs compared to reporting these events with all other drugs. The Breslow-Day statistic compared RORs across brand, AG, and other generics using a Bonferroni-corrected P<0.01. RESULTS A total of 27,150 events with lamotrigine, 13,950 events with carbamazepine, and 5077 events with oxcarbazepine were reported, with generics accounting for 27%, 41%, and 32% of reports, respectively. Although RORs for the majority of known AEs were different between brand and generics for all three drugs of interest (Breslow-Day P<0.001), RORs generally were similar for AG and generic comparisons. Generic lamotrigine and carbamazepine were more commonly involved in reports of suicide or suicidal ideation compared with the respective AGs based on a multiple comparison-adjusted P<0.01. SIGNIFICANCE Similar AED reporting rates were observed for the AG and generic comparisons for most outcomes and drugs, suggesting that brands and generics have similar reporting rates after accounting for generic perception biases. Disproportional suicide reporting was observed for generics compared with AGs and brand, although this finding needs further study.
Collapse
Affiliation(s)
- Md Motiur Rahman
- Auburn University, Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn, AL, USA.
| | - Yasser Alatawi
- Auburn University, Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn, AL, USA.
| | - Ning Cheng
- Auburn University, Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn, AL, USA.
| | - Jingjing Qian
- Auburn University, Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn, AL, USA.
| | - Annya V Plotkina
- Auburn University, Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn, AL, USA.
| | - Peggy L Peissig
- Marshfield Clinic Research Foundation, Biomedical Informatics Research Center, Marshfield, WI, USA.
| | - Richard L Berg
- Marshfield Clinic Research Foundation, Biomedical Informatics Research Center, Marshfield, WI, USA.
| | - David Page
- University of Wisconsin, School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, and Department of Computer Science, Madison, WI, USA.
| | - Richard A Hansen
- Auburn University, Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn, AL, USA.
| |
Collapse
|
3
|
Calderazzo M, Rende P, Gambardella P, De Sarro G, Gallelli L. A Case of Interstitial Lung Disease Probably Related to Rituximab Treatment. DRUG SAFETY - CASE REPORTS 2016; 2:8. [PMID: 27747720 PMCID: PMC5005575 DOI: 10.1007/s40800-015-0010-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A 44-year-old male developed interstitial lung disease (ILD) during treatment with rituximab (375 mg/m2 weekly intravenous × 4 weeks) for the management of immune thrombocytopenia (ITP). After 1 month of treatment he developed dyspnea, fever (38.9 °C), an increase of C-reactive protein (CRP) and white blood cells with hypoxemia, and decreased platelets. Chest X-ray and high-resolution computed tomography revealed diffuse bilateral lung infiltrates. He was diagnosed with severe ILD; rituximab was discontinued, and treatment with fluticasone combined with salmeterol, methylprednisolone, and omeprazole was started, with an improvement of symptoms over 15 days with normalization in CRP at 30 days. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's symptoms and the suspect drug. In conclusion, in ITP patients treated with rituximab, we suggest evaluating pulmonary endpoints through pharmaco-epidemiological observational studies.
Collapse
Affiliation(s)
| | - Pierandrea Rende
- Department of Health Science, University of Catanzaro, Viale Europa, Catanzaro, Italy.,Operative Unit of Clinical Pharmacology and Pharmacovigilance, Azienda Ospedaliera Mater Domini, Via T Campanella 115, Catanzaro, Italy
| | - Paolo Gambardella
- Department of Infectious Disease, ASP Lamezia Terme, Catanzaro, Italy
| | - Giovambattista De Sarro
- Department of Health Science, University of Catanzaro, Viale Europa, Catanzaro, Italy.,Operative Unit of Clinical Pharmacology and Pharmacovigilance, Azienda Ospedaliera Mater Domini, Via T Campanella 115, Catanzaro, Italy
| | - Luca Gallelli
- Department of Health Science, University of Catanzaro, Viale Europa, Catanzaro, Italy. .,Operative Unit of Clinical Pharmacology and Pharmacovigilance, Azienda Ospedaliera Mater Domini, Via T Campanella 115, Catanzaro, Italy.
| |
Collapse
|
4
|
Colosimo M, Grancini A, Daprai L, Giovanni Cimminiello A, Castelli C, Restelli A, Gallelli L, Torresani E. Involvement of Campylobacter jejuni in septic arthritis: a case report. JMM Case Rep 2015. [DOI: 10.1099/jmmcr.0.000095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Manuela Colosimo
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Anna Grancini
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Laura Daprai
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Aldo Giovanni Cimminiello
- Emergency Medicine Unit, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Cristina Castelli
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Antonella Restelli
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Luca Gallelli
- Department of Health Science, Operative Unit of Clinical Pharmacology and Pharmacovigilance, University of Catanzaro, Catanzaro, Italy
| | - Erminio Torresani
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| |
Collapse
|
5
|
Gallelli L, Maida F, Staltari O, Rende P, Russo E, Caroleo B, De Sarro G. Recurrence of atrial fibrillation after switching from brand to generic atenolol. J Pharmacol Pharmacother 2015; 6:39-41. [PMID: 25709353 PMCID: PMC4319249 DOI: 10.4103/0976-500x.149146] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2014] [Revised: 05/31/2014] [Accepted: 06/28/2014] [Indexed: 11/04/2022] Open
Abstract
Beta blockers are the initial treatment for rate control of supraventricular tachyarrhythmia in patients without a history of myocardial infarction or left ventricular dysfunction. In this article we report the recurrence of atrial fibrillation after switching to the generic formulation of atenolol.
Collapse
Affiliation(s)
- Luca Gallelli
- Department of Health Science, University of Catanzaro, Catanzaro, Italy
| | - Francesca Maida
- Department of Health Science, University of Catanzaro, Catanzaro, Italy
| | - Orietta Staltari
- Department of Health Science, University of Catanzaro, Catanzaro, Italy
| | - Pierandrea Rende
- Department of Health Science, University of Catanzaro, Catanzaro, Italy
| | - Emilio Russo
- Department of Health Science, University of Catanzaro, Catanzaro, Italy
| | - Benedetto Caroleo
- Department of Health Science, University of Catanzaro, Catanzaro, Italy
| | | |
Collapse
|